Marc Piroth

Erst-/Seniorautorenschaften

• Piroth MD, Baumann R, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Hehr T, Krug D, Röser A, Sedlmayer F, Souchon R, Wenz F, Sauer R. Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO).
• Heart toxicity from breast cancer radiotherapy: Current findings, assessment, and prevention. Strahlenther Onkol. 2019 Jan;195(1):1-12.    
• Lohmann P and Piroth MD (equally contributed), Sellhaus B, Weis J, Geisler S, Oros-Peusquens AM, Mohlberg H, Amunts K, Shah NJ, Galldiks N, Langen KJ. Correlation of Dynamic O-(2-[(18)F]Fluoroethyl)-L-Tyrosine Positron Emission Tomography, Conventional Magnetic Resonance Imaging, and Whole-Brain Histopathology in a Pretreated Glioblastoma: A Postmortem Study. World Neurosurg. 2018 Nov;119:653-660
• Piroth MD, Sautter-Bihl ML, Baumann R, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Krug D, Sedlmayer F,  Souchon R,  Wenz F, Sauer R. Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) Radiotherapy of the lymphatic drainage pathways in breast carcinoma: time for a reassessment Senologie 2017; 14: 92–98
• Piroth MD, Galldiks N, Pinkawa M, Holy R, Stoffels G, Ermert J, Mottaghy FM, Shah NJ, Langen KJ, Eble MJ. Relapse patterns after radiochemotherapy of glioblastoma with FET PET-guided boost irradiation and simulation to optimize radiation target volume Radiat Oncol. 2016 Jun 24;11(1):87
• Piroth MD, Petz D, Pinkawa M, Holy R, Eble MJ. Usefulness of a thermoplastic breast bra for breast cancer radiotherapy to reduce heart and lung dose – a prospective analysis. Strahlenther Onkol 2016 Sep;192(9): 609-16
• Piroth MD, Eble MJ. Intraoperative Radiotherapy with electrons Transl Cancer Res 2014;3:167-174
• Piroth MD, Bauerschlag D, Piroth DM, Maass N, Eble MJ Hypofraktionierung - Stellenwert in der adjuvanten Strahlentherapie des Mammakarzinoms Gynäkologe 2014;47:207-10
• Piroth MD, Liebenstund S, Galldiks N, Stoffels G, Shah NJ, Eble MJ, Coenen HH, Langen KJ. Monitoring of radiochemotherapy in patients with glioblastoma using O-(2-¹⁸Fluoroethyl)-L-tyrosine positron emission tomography: is dynamic imaging helpful? Mol Imaging 2013;12:388-95
• Piroth MD, Prasath J, Willuweit A, Stoffels G, Sellhaus B, van Osterhout A, Geisler S, Shah NJ, Eble MJ, Coenen HH, Langen KJ. Uptake of O-(2-[18F]fluoroethyl)-L-tyrosine in reactive astrocytosis in the vicinity of cerebral gliomas. Nucl Med Biol 2013;40:795-800
• Galldiks N, Langen KJ, Holy R, Pinkawa M, Stoffels G, Nolte KW, Kaiser HJ, Filss CP, Fink GR, Coenen HH, Eble MJ, Piroth MD. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI. J Nucl Med 2012;53:1048-57
• Piroth MD, Fischedick K, Wein B, Heindrichs U, Piroth DM, Holy R, Pinkawa M, Eble MJ. Fat necrosis and parenchymal scarring after breast-conserving surgery and radiotherapy with an intraoperative electron or fractionated, percutaneous boost: a retrospective comparison. Breast Cancer 2012;21:409-14
• Piroth MD, Pinkawa M, Holy R, Klotz J, Schaar S, Stoffels G, Galldiks N, Coenen HH, Kaiser HJ, Langen KJ, Eble MJ. Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. Results of a prospective phase II study. Strahlenther Onkol 2012;188:334-9
• Piroth MD, Holy R, Pinkawa M, Stoffels G, Kaiser HJ, Galldiks N, Herzog H, Coenen HH, Eble MJ, Langen KJ. Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. Radiother Oncol 2011;99:218-24
• Piroth MD, Pinkawa M, Holy R, Klotz J, Nussen S, Stoffels G, Coenen HH, Kaiser HJ, Langen KJ, Eble MJ. Prognostic value of early [18F] fluoroethyltyrosine positron emission tomography after radio-chemotherapy in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2011;80:176-84
• Piroth MD, Heindrichs U, Pinkawa M, Piroth DM, Schmachtenberg A, Perez-Bouza A, Maass N, Eble MJ. Intraoperative Radiotherapie (IORT) des Mammakarzinoms mit Elektronen – eigene Erfahrungen, aktuelle Aspekte und Literaturübersicht. Geburtsh Frauenheilk 2010;70:219–225
• Piroth MD, Pinkawa M, Holy R, Stoffels G, Demirel C, Attieh C, Kaiser HJ, Langen KJ, Eble MJ. Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme—a dosimetric comparison. Radiat Oncol 2009;4:57
• Piroth MD, Piroth DM, Pinkawa M, Woodruff SG, Holy R, Eble MJ. Immediate reconstruction with an expander/implant following ablatio mammae because of breast cancer : side effects and cosmetic results after adjuvant chest wall radiotherapy. Strahlenther Onkol 2009;185:669-74
• Piroth MD, Pinkawa M, Gagel B, Stanzel S, Asadpour B, Eble MJ. Sequencing chemotherapy and radiotherapy in locoregional advanced breast cancer patients after mastectomy - a retrospective analysis. BMC Cancer 2008;8:114       
• Piroth MD, Gagel B, Pinkawa M, Stanzel S, Asadpour B, Eble MJ. Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors. Strahlenther Onkol 2007;183:695-702
• Piroth MD, Hensley F, Wannenmacher M, Zierhut D. Male gonadal dose in adjuvant 3-d-pelvic irradiation after anterior resection of rectal cancer. Influence to fertility. Strahlenther Onkol 2003;179:754-9
• Piroth MD, Krempien R, Wannenmacher M, Zierhut D. Radiation recall dermatitis from docetaxel. Onkologie 2002;25:438-40
• Piroth MD, Zierhut D, van Kampen M, Sroka-Perez G, Wannenmacher M. Lung dose depending on exact patient positioning during total body irradiation (TBI)- Isoeffectiveness considerations to assess the risk of interstitial pneumonia after TBI. Strahlenther Onkol 2002;178:43-9

Literaturkommentare (Pubmed-gelistet)

• Piroth MD, Mücke R, Micke O. [Antioxidants and selenium should not be lumped together into one category-evaluation of supplementation during chemotherapy or radiotherapy for breast cancer]. Strahlenther Onkol. 2019 Sep;195(9):857-860.
• Piroth MD. [Estimating the long-term risks of breast cancer radiotherapy: evidence for lungs and heart]. Strahlenther Onkol. 2018 Jul;194(7):693-694.
• Piroth MD. [Radiation Therapy to the Plexus Brachialis in Breast Cancer Patients: Analysis of Paresthesia in Relation to Dose and Volume]. Strahlenther Onkol. 2015;191:892-4
• Piroth MD. [Risk-adapted targeted intraoperative radiotherapy versus whole breast irradiation in breast cancer patients]. Strahlenther Onkol 2014;190:767-9
• Piroth MD [Risks of unfavorable cosmetic and toxicity after percutaneous accelerated partial breast irradiation (APBI). Interim analysis from the Canadian RAPID trial]. Strahlenther Onkol 2013;189:1054-5
• Piroth MD Intraoperative radiotherapy of the breast - really a valid option or “only” comfortable. Gland Surg 2013;2:114-5

Buchbeitrag

• Piroth, MD Intraarterielle Therapie von Lebermetastasen, In: Radiologische Technik und klinische Ergebnisse der intraarteriellen Chemotherapie (Hrsg.: Piroth, HD), Schnetztor Verlag Konstanz 2002:25-39

Co-Autorenschaften

• Hehr T, Baumann R, Budach W, Duma MN, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Krug D, Piroth MD, Sedlmayer F, Souchon R, Wenz F, Sauer R. Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO). Radiotherapy after skin-sparing mastectomy with immediate breast reconstruction in intermediate-risk breast cancer : Indication and technical considerations. Strahlenther Onkol. 2019 Nov;195(11):949-963.
• Duma MN, Baumann R, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Hehr T, Krug D, Piroth MD, Sedlmayer F, Souchon R, Sauer R; Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO). Heart-sparing radiotherapy techniques in breast cancer patients: a recommendation of the breast cancer expert panel of the German society of radiation oncology (DEGRO). Strahlenther Onkol. 2019 Oct;195(10):861-871.
• Rosenkranz E, Thissen A, Siegel S, Piroth M, Clusmann H, Gebauer J, Brabant G, Kreitschmann-Andermahr I. Melatonin secretion following brain midline irradiation is diminished, but not correlated with subjective sleep disturbances. Clin Endocrinol (Oxf). 2018 Dec;89(6):870-877.
• Krug D, Baumann R, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Hehr T, Piroth MD, Sedlmayer F, Souchon R, Wenz F, Sauer R; Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO). Neoadjuvant chemotherapy for breast cancer-background for the indication of locoregional treatment. Strahlenther Onkol. 2018 Sep;194(9):797-805.
• Krug D, Baumann R, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Hehr T, Piroth MD, Sedlmayer F, Souchon R, Wenz F, Sauer R. Individualization of post-mastectomy radiotherapy and regional nodal irradiation based on treatment response after neoadjuvant chemotherapy for breast cancer : A systematic review. Strahlenther Onkol. 2018 Jul;194(7):607-618.
• Schubert C, Waletzko O, Weiss C, Voelzke D, Toperim S, Roeser A, Puccini S, Piroth M, Mehrens C, Kueter JD, Hierholz K, Gerull K, Fogliata A, Block A, Cozzi L. Intercenter validation of a knowledge based model for automated planning of volumetric modulated arc therapy for prostate cancer. The experience of the German RapidPlan Consortium. PLoS One. 2017 May 22;12(5)
• Krug D, Baumann R, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Piroth MD, Sautter-Bihl ML, Sedlmayer F, Souchon R, Wenz F, Sauer R; Breast cancer expert panel of the German Society of Radiation Oncology (DEGRO). Current controversies in radiotherapy for breast cancer. Radiat Oncol. 2017 Jan 23;12(1)
• Harms W, Budach W, Dunst J, Feyer P, Fietkau R,·Haase W, Piroth MD, Krug D, Sautter-Bihl ML, Sedlmayer F, Souchon R, Wenz F, Sauer R. Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO). DEGRO practical guidelines for radiotherapy of breast cancer VI: Therapy of locoregional breast cancer recurrences. Strahlenther Onkol 2016
• Budach W, Matuschek C, Bölke E, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Piroth MD, Sautter-Bihl ML, Sedlmayer F, Souchon R, Wenz F, Sauer R. Breast Cancer Expert Panel of German Society of Radiation Oncology (DEGRO). DEGRO practical guidelines for radiotherapy of breast cancer V: Therapy for locally advanced and inflammatory breast cancer, as well as local therapy in cases with synchronous distant metastases. Strahlenther Onkol 2015;191:623-33
• Sautter-Bihl ML, Sedlmayer F, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Piroth MD, Souchon R, Wenz F, Sauer R. Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO). How nescience may obscure evidence. Strahlenther Onkol 2014;190:861-3
• Wenz F, Sperk E, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Piroth MD, Sautter-Bihl ML, Sedlmayer F, Souchon R, Fussl C, Sauer R. Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO). DEGRO practical guidelines for radiotherapy of breast cancer IV : Radiotherapy following mastectomy for invasive breast cancer. Strahlenther Onkol 2014;190:705-14
• Kocher M, Wittig A, Piroth MD, Treuer H, Seegenschmiedt H, Ruge M, Grosu AL, Guckenberger M. Stereotactic radiosurgery for treatment of brain metastases. A report of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlenther Onkol 2014;190:521-32
• Sautter-Bihl ML, Sedlmayer F, Budach W, Dunst J, Feyer P, Fietkau R, Fussl C, Haase W, Harms W, Piroth MD, Souchon R, Wenz F, Sauer R. Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO). DEGRO practical guidelines: radiotherapy of breast cancer III--radiotherapy of the lymphatic pathways. Strahlenther Onkol 2014;190:342-51
• Pinkawa M, Djukic V, Klotz J, Petz D, Piroth MD, Holy R, Eble MJ. Hematologic changes during prostate cancer radiation therapy are dependent on the treatment volume. Future Oncol 2014;10:835-43
• Weinandy A, Piroth MD, Goswami A, Nolte K, Sellhaus B, Gerardo-Nava J, Eble M, Weinandy S, Cornelissen C, Clusmann H, Lüscher B, Weis J. Cetuximab induces eme1-mediated DNA repair: a novel mechanism for cetuximab resistance. Neoplasia 2014;16:207-20
• Pinkawa M, Klotz J, Djukic V, Schubert C, Escobar-Corral N, Caffaro M, Piroth MD, Holy R, Eble MJ Learning curve in the application of a hydrogel spacer to protect the rectal wall during radiotherapy of localized prostate cancer. Urology 2013;82:963-8
• Pinkawa M, Bornemann C, Escobar-Corral N, Piroth MD, Holy R, Eble MJ. Treatment planning after hydrogel injection during radiotherapy of prostate cancer. Strahlenther Onkol 2013;189:796-800
• Pinkawa M, Piroth MD, Holy R, Escobar-Corral N, Caffaro M, Djukic V, Klotz J, Eble MJ. Spacer stability and prostate position variability during radiotherapy for prostate cancer applying a hydrogel to protect the rectal wall. Radiother Oncol 2013;106:220-4
• Pinkawa M, Piroth MD, Holy R, Djukic V, Klotz J, Pfister D, Heidenreich A, Eble MJ. Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy. Radiat Oncol 2012;7:209
• Pinkawa M, Piroth MD, Holy R, Escobar-Corral N, Caffaro M, Djukic V, Klotz J,Eble MJ. Quality of life after intensity-modulated radiotherapy for prostate cancer with a hydrogel spacer. Matched-pair analysis. Strahlenther Onkol 2012;188:917-25
• Galldiks N, Stoffels G, Filss CP, Piroth MD, Sabel M, Ruge MI, Herzog H, Shah NJ, Fink GR, Coenen HH, Langen KJ. Role of O-(2-(18)F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis. J Nucl Med 2012;53:1367-74
• Pinkawa M, Holy R, Piroth MD, Klotz J, Pfister D, Heidenreich A, Eble MJ. Urinary morbidity after permanent prostate brachytherapy - impact of dose to the urethra vs. sources placed in close vicinity to the urethra. Radiother Oncol 2012;103:247-51
• Pinkawa M, Piroth MD, Holy R, Klotz J, Djukic V, Corral NE, Caffaro M, Winz OH, Krohn T, Mottaghy FM, Eble MJ. Dose-escalation using intensity-modulated radiotherapy for prostate cancer - evaluation of quality of life with and without (18)F-choline PET-CT detected simultaneous integrated boost. Radiat Oncol 2012;7:14
• Pinkawa M, Corral NE, Caffaro M, Piroth MD, Holy R, Djukic V, Otto G, Schoth F, Eble MJ. Application of a spacer gel to optimize three-dimensional conformal and intensity modulated radiotherapy for prostate cancer. Radiother Oncol 2011;100:436-41
• Pinkawa M, Piroth MD, Holy R, Djukic V, Klotz J, Krenkel B, Eble MJ. Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer. Strahlenther Onkol 2011;187:479-84
• Holy R, Piroth M, Pinkawa M, Eble MJ. Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther Onkol 2011;187:245-51
• Pinkawa M, Piroth MD, Holy R, Fischedick K, Klotz J, Székely-Orbán D, Eble MJ. Quality of life after whole pelvic versus prostate-only external beam radiotherapy for prostate cancer: a matched-pair comparison. Int J Radiat Oncol Biol Phys 2011;81:23-8
• Pinkawa M, Holy R, Piroth MD, Klotz J, Nussen S, Krohn T, Mottaghy FM, Weibrecht M, Eble MJ. Intensity-modulated radiotherapy for prostate cancer implementing molecular imaging with 18F-choline PET-CT to define a simultaneous integrated boost. Strahlenther Onkol 2010;186:600-6
• Pinkawa M, Piroth MD, Holy R, Fischedick K, Schaar S, Borchers H, Heidenreich A, Eble MJ. Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer. Radiother Oncol 2010;96:25-9
• Pinkawa M, Holy R, Piroth MD, Fischedick K, Schaar S, Székely-Orbán D, Eble MJ. Consequential late effects after radiotherapy for prostate cancer – a prospective longitudinal quality of life study. Radiat Oncol 2010;5:27
• Pinkawa M, Piroth MD, Fischedick K, Holy R, Klotz J, Nussen S, Krenkel B, Eble MJ. Impact of the target volume (prostate alone vs. prostate with seminal vesicles) and fraction dose (1.8 Gy vs. 2.0 Gy) on quality of life changes after external-beam radiotherapy for prostate cancer. Strahlenther Onkol 2009;185:724-30
• Pinkawa M, Piroth MD, Fischedick K, Nussen S, Klotz J, Holy R, Eble MJ. Self-assessed bowel toxicity after external beam radiotherapy for prostate cancer--predictive factors on irritative symptoms, incontinence and rectal bleeding. Radiat Oncol 2009;4:36
• Pinkawa M, Piroth MD, Holy R, Klotz J, Nussen S, Borchers H, Heidenreich A, Eble MJ. Rectal morbidity after permanent interstitial brachytherapy for prostate cancer--impact of day 1 vs. day 30 computed tomography-based postimplant dosimetry. Brachytherapy 2010;9:1-7
• Thiele F, Ehmer J, Piroth MD, Eble MJ, Coenen HH, Kaiser HJ, Schaefer WM, Buell U, Boy C. The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with glioblastoma. Phys Med Biol 2009;54:5525-39
• Pinkawa M, Attieh C, Piroth MD, Holy R, Nussen S, Klotz J, Hawickhorst R, Schäfer W, Eble MJ. Dose-escalation using intensity-modulated radiotherapy for prostate cancer--evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boost. Radiother Oncol 2009;93:213-9
• Pinkawa M, Fischedick K, Gagel B, Piroth MD, Asadpour B, Klotz J, Borchers H, Jakse G, Eble MJ. Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment. BMC Cancer 2009;9:296
• Pinkawa M, Piroth MD, Asadpour B, Gagel B, Fischedick K, Siluschek J, Kehl M, Krenkel B, Eble MJ. Neoadjuvant hormonal therapy and external-beam radiotherapy versus external- beam irradiation alone for prostate cancer. A quality-of-life analysis. Strahlenther Onkol 2009;185:101-8
• Pinkawa M, Asadpour B, Piroth MD, Gagel B, Klotz J, Fischedick K, Borchers H, Jakse G, Eble MJ. Rectal dosimetry following prostate brachytherapy with stranded seeds--comparison of transrectal ultrasound intra-operative planning (day 0) and  computed tomography-postplanning (day 1 vs. day 30) with special focus on sources placed close to the rectal wall. Radiother Oncol 2009;91:207-12
• Pinkawa M, Asadpour B, Piroth MD, Gagel B, Nussen S, Kehl M, Borchers H, Jakse G, Eble MJ. Health-related quality of life after permanent I-125 brachytherapy and conformal external beam radiotherapy for prostate cancer—a matched-pair comparison. Radiother Oncol 2009;91:225-31
• Pinkawa M, Gagel B, Piroth MD, Fischedick K, Asadpour B, Kehl M, Klotz J, Eble MJ. Erectile dysfunction after external beam radiotherapy for prostate cancer. Eur Urol 2009;55:227-34
• Pinkawa M, Pursch-Lee M, Asadpour B, Gagel B, Piroth MD, Klotz J, Nussen S, Eble MJ. Image-guided radiotherapy for prostate cancer. Implementation of ultrasound-based prostate localization for the analysis of inter- and intrafraction organ motion. Strahlenther Onkol 2008;184:679-85
• Pinkawa M, Gagel B, Asadpour B, Piroth MD, Klotz J, Borchers H, Jakse G, Eble MJ. Seed displacements after permanent brachytherapy for prostate cancer in dependence on the prostate level. Strahlenther Onkol 2008;184:520-5
• Pinkawa M, Fischedick K, Asadpour B, Gagel B, Piroth MD, Holy R, Krenkel B, Eble MJ. Health-related quality of life after adjuvant and salvage postoperative  radiotherapy for prostate cancer - a prospective analysis. Radiother Oncol 2008;88:135-9
• Pinkawa M, Fischedick K, Asadpour B, Gagel B, Piroth MD, Nussen S, Eble MJ. Toxicity profile with a large prostate volume after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:83-9
• Pinkawa M, Asadpour B, Gagel B, Piroth MD, Borchers H, Jakse G, Eble MJ. Evaluation of source displacement and dose--volume changes after permanent prostate brachytherapy with stranded seeds. Radiother Oncol 2007;84:190-6
• Gagel B, Piroth M, Pinkawa M, Reinartz P, Zimny M, Kaiser HJ, Stanzel S, Asadpour B, Demirel C, Hamacher K, Coenen HH, Scholbach T, Maneschi P, DiMartino E, Eble MJ. pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? BMC Cancer 2007;7:113
• Gagel B, Piroth M, Pinkawa M, Reinartz P, Krohn T, Kaiser HJ, Stanzel S, Breuer C, Asadpour B, Schmachtenberg A, Eble MJ. Sequential (gemcitabine/vinorelbine) and concurrent (gemcitabine) radiochemotherapy with FDG-PET-based target volume definition in locally advanced non-small cell lung cancer: first results of a phase I/II study. BMC Cancer 2007;7:112
• Pinkawa M, Asadpour B, Siluschek J, Gagel B, Piroth MD, Demirel C, Eble MJ. Bladder extension variability during pelvic external beam radiotherapy with a full or empty bladder. Radiother Oncol 2007;83:163-7
• Pinkawa M, Fischedick K, Piroth MD, Gagel B, Borchers H, Jakse G, Eble MJ. Prostate-specific antigen kinetics after brachytherapy or external beam radiotherapy and neoadjuvant hormonal therapy. Urology 2007;69:129-33
• Pinkawa M, Siluschek J, Gagel B, Piroth MD, Demirel C, Asadpour B, Eble MJ. Postoperative radiotherapy for prostate cancer : evaluation of target motion and treatment techniques (intensity-modulated versus conformal radiotherapy). Strahlenther Onkol 2007;183:23-9
• Gagel B, Demirel C, Kientopf A, Pinkawa M, Piroth M, Stanzel S, Breuer C, Asadpour B, Jansen T, Holy R, Wildberger JE, Eble MJ. Active breathing control (ABC): determination and reduction of breathing-induced organ motion in the chest. Int J Radiat Oncol Biol Phys 2007;67:742-9
• Pinkawa M, Fischedick K, Piroth MD, Gagel B, Borchers H, Jakse G, Eble MJ. Health-related quality of life after permanent interstitial brachytherapy for prostate cancer: correlation with postimplant CT scan parameters. Strahlenther Onkol 2006;182:660-5
• Gagel B, DiMartino E, Schramm O, Pinkawa M, Piroth M, Demirel C, Maneschi P, Stanzel S, Asadpour B, Westhofen M, Eble MJ. Contrast-enhanced color duplex sonography (CDS): an alternative for the evaluation of therapy-relevant tumor oxygenation? Strahlenther Onkol 2006;182:604-9
• Pinkawa M, Gagel B, Piroth MD, Borchers H, Jakse G, Eble MJ. Changes of dose delivery distribution within the first month after permanent interstitial brachytherapy for prostate cancer. Strahlenther Onkol 2006;182:525-30
• Pinkawa M, Fischedick K, Gagel B, Piroth MD, Borchers H, Jakse G, Eble MJ. Association of neoadjuvant hormonal therapy with adverse health-related quality of life after permanent iodine-125 brachytherapy for localized prostate cancer. Urology 2006;68:104-9
• Gagel B, Piroth M, Pinkawa M, Reinartz P, Zimny M, Fischedick K, Stanzel S, Breuer C, Skobel E, Asadpour B, Schmachtenberg A, Buell U, Eble MJ. Gemcitabine concurrent with thoracic radiotherapy after induction chemotherapy with gemcitabine/vinorelbine in locally advanced non-small cell lung cancer: a phase I study. Strahlenther Onkol 2006;182:263-9
• Gagel B, Reinartz P, Demirel C, Kaiser HJ, Zimny M, Piroth M, Pinkawa M, Stanzel S, Asadpour B, Hamacher K, Coenen HH, Buell U, Eble MJ. [18F]fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer 2006;6:51.
• Pinkawa M, Fischedick K, Asadpour B, Gagel B, Piroth MD, Eble MJ. Low-grade toxicity after conformal radiation therapy for prostate cancer--impact of bladder volume. Int J Radiat Oncol Biol Phys 2006;64:835-41
• Pinkawa M, Fischedick K, Treusacher P, Asadpour B, Gagel B, Piroth MD, Borchers H, Jakse G, Eble MJ. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study. Radiother Oncol 2006 ;78:41-6
• Pinkawa M, Asadpour B, Gagel B, Piroth MD, Holy R, Eble MJ. Prostate position variability and dose-volume histograms in radiotherapy for prostate cancer with full and empty bladder. Int J Radiat Oncol Biol Phys 2006;64:856-61
• Martin M, Zierhut D, Piroth M, Gutwein S, Debus J, Dithmar S. Solitary iris metastasis from breast cancer. Effective local therapy with electron beam irradiation. Ophthalmologe 2006;103:48-51